Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof

US11752172B2 · kind B2 · utility

Assignees

• Nova Southeastern University · US
• SABANCI UNIVERSITESI · TR

Inventors

• Tolga Sutlu · Işıklar, TR
• Adil Doganay DURU · Fort Lauderdale, US
• Batu ERMAN · Işıklar, TR

Key dates

• Filing date: Jan 4, 2018
• Grant date: Sep 12, 2023
• Expiry date: Jul 27, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR a and β chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).